Resumo
Objetivo: Analisar as repercussões estruturais cardiovasculares do hiperaldosteronismo primário, com ênfase nos achados de imagem, nos mecanismos fisiopatológicos e nos efeitos da adrenalectomia sobre o remodelamento miocárdico e vascular. Métodos: Trata-se de uma revisão integrativa da literatura, de caráter descritivo e abordagem qualitativa, realizada nas bases PubMed, Biblioteca Virtual em Saúde (BVS), SciELO e Cochrane Library. A pergunta norteadora foi elaborada segundo a estratégia PICO, considerando pacientes com hiperaldosteronismo, suas repercussões cardiovasculares estruturais, comparação com hipertensão essencial ou controles saudáveis e os desfechos relacionados à hipertrofia, fibrose e remodelamento cardíaco. Foram incluídos artigos originais publicados entre 2020 e 2025, nos idiomas português, inglês e espanhol, resultando na seleção final de 10 estudos. Resultados: A amostra compreendeu 4.130 participantes. Observou-se maior prevalência de hipertrofia ventricular esquerda, fibrose miocárdica, remodelamento biventricular, rigidez arterial e disfunção microvascular em indivíduos com hiperaldosteronismo quando comparados à hipertensão essencial. Além disso, alterações estruturais foram identificadas mesmo em fases subclínicas da doença. Estudos de seguimento demonstraram regressão parcial dessas alterações após tratamento específico, especialmente após adrenalectomia. Considerações finais: O hiperaldosteronismo primário associa-se a dano cardiovascular além dos efeitos da hipertensão isolada. O diagnóstico precoce e o tratamento direcionado favorecem a reversão do remodelamento cardíaco e vascular, contribuindo para melhor prognóstico clínico.
Referências
ADLER GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 2025; 110.
ANANDA RA, et al. Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults. Circulation, 2024; 150(25): 2019–2030.
AZIZAN E, DRAKE W, BROWN MJ. Primary aldosteronism: molecular medicine meets public health. Nature Reviews Nephrology, 2023.
BROWN JM, et al. Characterizing the Origins of Primary Aldosteronism. Hypertension, 2025; 82(2): 306–318.
CHEN YL, et al. Myocardial fibrosis in primary aldosteronism. Frontiers in Endocrinology, 2025; 16.
COHEN JB, et al. Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys. Annual Review of Medicine, 2022; 74(1): 217–230.
HUANG M, et al. Relationship between vascular ageing and left ventricular geometry in patients with newly diagnosed primary aldosteronism. Frontiers in Endocrinology, 2022; 13: 961882.
HUNDEMER GL, et al. Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study. Circulation, 2024; 149(2): 124–134.
INOUE K, et al. Primary Aldosteronism and Risk of Cardiovascular Outcomes: Genome-Wide Association and Mendelian Randomization Study. Journal of the American Heart Association, 2024; 13(15).
LI S, et al. Target organ damage in untreated hypertensive patients with primary aldosteronism. Journal of Clinical Hypertension, 2024; 26(7): 789–796.
NANBA K, et al. Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. The Journal of Clinical Endocrinology & Metabolism, 2022; 107(9): 2473–2482.
NARUSE M, et al. Adrenal Venous Sampling for Subtype Diagnosis of Primary Hyperaldosteronism. Endocrinology and Metabolism, 2021; 36(5): 965–973.
PAN CT, et al. Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism. Frontiers in Endocrinology, 2021; 12: 646097.
QUENCER KB, RUGGE JB, SENASHOVA O. Primary Aldosteronism. American Family Physician, 2023; 108(3): 273–277.
SCHOLL UI. Genetics of Primary Aldosteronism. Hypertension, 2022; 79: 887–897.
SOUZA MT, SILVA MD, CARVALHO R. Revisão integrativa: o que é e como fazer. Einstein, 2010; 8(1): 102–108.
ŚPIEWAK M, et al. Right Ventricular Structure and Function in Patients with Primary Aldosteronism: A Cardiac Magnetic Resonance Study. Journal of Clinical Medicine, 2025; 14(15): 5367.
REINCKE M, et al. Diagnosis and treatment of primary aldosteronism. The Lancet Diabetes & Endocrinology, 2021; 9(12): 876–892.
TANG L, et al. The differentiation between primary aldosteronism and essential hypertension in left ventricular remodeling before and after treatment: a follow-up study with quantitative stress cardiac magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2025; 15(12): 12116–12132.
WU T, et al. Left Ventricular Remodeling in Patients with Primary Aldosteronism: A Prospective Cardiac Magnetic Resonance Imaging Study. Korean Journal of Radiology, 2021; 22(10): 1619–1627.
ZHOU F, et al. CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in
Primary Aldosteronism Patients. Frontiers in Endocrinology, 2021; 12: 672557.
